Values
Our identity
Consumer protection
Employees & partners
Mission
Environment
Code of conduct
Whistleblowing
Corporate compliance
Policy for the
Prevention of Corruption
Sustainability report
Benefit Company - B Corp
Kip for social
Corporate
Innovative PMI
Nutraceuticals
Profile and organization
Research and development
Company validations
Product certifications
and Declarations
Patents
Trademarks
KIP Academy
Quality & protection
Raw materials choice
Attention to food intolerances
Study about the packs
Information in braille
Tamper Evident system
Conservation and transportation
The nutraceutic module
Products
All products
Neurological Line
Kymax
®
Declinex
®
Uro-Gynecological Line
KIPFeR
®
Almetax
®
Almetax Easy
®
Ivuxur
®
sachets
Ivuxur
®
tablets
Miledix
®
Xinprox
®
Osteoarticular line
Dolatrox
®
Milesax
®
Xinepa
®
Xinepa Easy
®
Doltendix
®
Immunological Line
KIP
®
IMMUNO
Other products
Dolatrox hcc
®
Media
News
Press review
Press kit
Contact Media Relations
Contact
For consumers
For doctors
For pharmacies and health stores
For distributors
For other subjects
Work with us
Where we are
Legal notice
Privacy
E-commerce
Language
Italiano
English
News
News from the world KOLINPHARMA
22/05/2024
- published at 15.29
KOLINPHARMA®: new patent in China for Doltendix®
KOLINPHARMA® achieved the first patent in China for Doltendix®
29/03/2024
- published at 15.36
KOLINPHARMA
®
: has received the prize Credit Reputation Award
20/03/2024
- published at 15.27
KOLINPHARMA
®
expands the range of products with the launch of Kymax
®
In recent decades, world demographics have changed significantly with a progressive aging of the global population.
10/01/2024
- published at 14.45
Kolinpharma® launches KIPFeR® following agreement with Nemysis LTD
Kipfer is the new dietary supplement designed for all situations in which the body is deficient in iron.
09/01/2024
- published at 17.15
Kolinpharma® is pleased to announce the launch of KIPFeR®
KIPFeR® is the nanoparticle iron supplement that Kolinpharma® has launched on the market following a new agreement with Nemysis LTD.
06/03/2023
- published at 15.15
Kolinpharma
®
for gender equity a PMIHeroes
Rita Paola Petrelli was being a guest on the podcast PMIHeroes in Ifis Bank
06/12/2022
- published at 15.23
KOLINPHARMA
®
: has achieved the first patent for Xinprox
®
Now, Kolinpharma has 46 patents in total
23/11/2022
- published at 15.34
KOLINPHARMA
®
: has achieved the award as “Leader of growth 2023” for the fifth consecutive year
Even this year the company is one between 500 Italian enterprises that they were distinguished for the major growth of turnover
25/10/2022
- published at 16.47
KOLINPHARMA
®
signs an agreement with ASTAREAL
®
AB for distribution in the Asian market
An important three-year agreement for distribution of products in Mainland China, Hong Kong, Macao and Taiwan
05/08/2021
- published at 16.06
Kolinpharma
®
at VITAFOODS Europe 2021 in Geneva and at CPHI Worldwide 2021 in Milan
KOLINPHARMA
®
strengthens its marketing and brand awareness strategy
26/08/2020
- published at 14.14
KOLINPHARMA
®
expands its product portfolio with IVUXUR
®
TABLETS.
KOLINPHARMA
®
presents the new product IVUXUR
®
TABLETS, which is added to the other 9 patented or patent pending products
16/04/2020
- published at 14.49
KOLINPHARMA
®
:first patent for XINEPA
®
in Israel and fifth outside Italy
Xinepa
®
is a nutraceutical product already in possession of a double patent in Italy
10/03/2020
- published at 16.45
KOLINPHARMA
®
obtains the patent in the U.S. of Dolatrox
®
It is the fourth patent that is added to Ivuxur
®
and to the 2 of Xinepa
®
24/05/2019
- published at 10.54
KOLINPHARMA
®
invests in product quality and safety
Strict product controls guarantee quality and safety for the consumer.
02/02/2018
- published at 10.05
The attention to the pharmaceutical forms for an easier patient’s compliance.
The company complements to the traditional pharmaceutical forms, new solutions, easy in their use.
09/01/2018
- published at 12.16
KOLINPHARMA
®
in the European research
Since 2017, the company faced an international research.
08/01/2018
- published at 10.16
Tamper evident: ever-changing patented technology
The company adopted a packaging closure, which is usable even for blind people.
02/01/2018
- published at 10.28
Research and Development team (R&D): effectiveness and innovation
The company’s beating heart, the R&D team, is part of the company.
> News archive
Media
News
Almetax Easy and tablets
Certified products
Company validations
Consumer Protection
Corporate compliance
Dolatrox
Homepage
Ivuxur
Milesax
Nutraceuticals
Profile and organization
Research and development
Respect the environment
Xinepa Easy and tablets
Press review
Press Kit
Contact media relations
“Science accuracy and listen to people”
“Science accuracy and listen to people”